New US nod widens the net for Entresto
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Mid-stage angioedema hit sends Kalvista though the roof
The first oral rescue therapy for acute attacks is on the horizon.
Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
